211At labeled substance P (5-11) as potential radiopharmaceutical for glioma treatment
- PMID: 28683361
- DOI: 10.1016/j.nucmedbio.2017.05.008
211At labeled substance P (5-11) as potential radiopharmaceutical for glioma treatment
Abstract
Introduction: The purposes of the present work were to label substance P (5-11) with 211At using a rhodium(III) complex with a bifunctional ligand-2-(1,5,9,13-tetrathiacyclohexadecan-3-yloxy)acetic acid ([16aneS4]-COOH) and to assess the in vitro stability and toxicity of the obtained radiobioconjugate.
Methods: Two approaches were evaluated to obtain 131I/211At-Rh[16aneS4]-SP5-11 radiobioconjugates, based on 2-step and 1-step syntheses. In the first method 131I/211At-Rh[16aneS4]-COOH complexes were obtained that required further coupling to a biomolecule. In the second approach, the bioconjugate [16aneS4]-SP5-11 was synthesized and further labeled with 131I and 211At through the utilization of a Rh(III) metal cation bridge. The synthesized compounds were analyzed by HPLC, TLC and paper electrophoresis.
Results: The 131I/211At-Rh[16aneS4]-COOH complexes were obtained in high yield and possessed good stability in PBS and CSF. Preliminary studies on coupling of 131I-Rh[16aneS4]-COOH to substance P (5-11) in 2-step synthesis showed that this procedure was too long with respect to 211At half-life, prompting us to improve it by finally using a 1-step synthesis. This strategy not only shortened the labeling time, but also increased final yield of 131I/211At-Rh[16aneS4]-SP5-11 radiobioconjugates. The stability of both compounds in PBS and CSF was high. Toxicity studies with the 211At-Rh[16aneS4]-SP5-11 demonstrated that radiobioconjugate significantly reduced T98G cell viability in a dose dependent manner reaching 20% of survival at the highest radioactivity 1200kBq/mL.
Conclusions: The radiobioconjugate 211At-Rh[16aneS4]-SP5-11 revealed its potential in killing glioma T98G cells during in vitro studies; therefore further animal studies to are required to determine its in vivo stability and treatment potential in normal and xenografted mice.
Keywords: Astatine-211; Macrocyclic thioether; Radioiodination; Rhodium complexes; Substance P.
Copyright © 2017 Elsevier Inc. All rights reserved.
Similar articles
-
Application of Neurokinin-1 Receptor in Targeted Strategies for Glioma Treatment. Part I: Synthesis and Evaluation of Substance P Fragments Labeled with 99mTc and 177Lu as Potential Receptor Radiopharmaceuticals.Molecules. 2018 Oct 5;23(10):2542. doi: 10.3390/molecules23102542. Molecules. 2018. PMID: 30301182 Free PMC article.
-
Preparation of Rh[16aneS4-diol](211)At and Ir[16aneS4-diol](211)At complexes as potential precursors for astatine radiopharmaceuticals. Part I: Synthesis.Bioconjug Chem. 2008 Apr;19(4):958-65. doi: 10.1021/bc700413r. Epub 2008 Mar 14. Bioconjug Chem. 2008. PMID: 18338858 Free PMC article.
-
Stability and in vivo behavior of Rh[16aneS4-diol]211 at complex: a potential precursor for astatine radiopharmaceuticals.Nucl Med Biol. 2015 May;42(5):439-445. doi: 10.1016/j.nucmedbio.2014.12.011. Epub 2014 Dec 23. Nucl Med Biol. 2015. PMID: 25687450 Free PMC article.
-
Targeted Radiolabeled Compounds in Glioma Therapy.Semin Nucl Med. 2016 May;46(3):243-9. doi: 10.1053/j.semnuclmed.2016.01.009. Semin Nucl Med. 2016. PMID: 27067505 Review.
-
Synthesis Principle and Practice with Radioactive Iodines and Astatine: Advances Made So Far.J Org Chem. 2024 Sep 6;89(17):11837-11863. doi: 10.1021/acs.joc.4c00593. Epub 2024 Aug 22. J Org Chem. 2024. PMID: 39173032 Review.
Cited by
-
Application of Neurokinin-1 Receptor in Targeted Strategies for Glioma Treatment. Part I: Synthesis and Evaluation of Substance P Fragments Labeled with 99mTc and 177Lu as Potential Receptor Radiopharmaceuticals.Molecules. 2018 Oct 5;23(10):2542. doi: 10.3390/molecules23102542. Molecules. 2018. PMID: 30301182 Free PMC article.
-
Novel Bifunctional [16]aneS4-Derived Chelators for Soft Radiometals.Molecules. 2021 Jul 29;26(15):4603. doi: 10.3390/molecules26154603. Molecules. 2021. PMID: 34361752 Free PMC article.
-
Targeted and Nontargeted α-Particle Therapies.Annu Rev Biomed Eng. 2018 Jun 4;20:73-93. doi: 10.1146/annurev-bioeng-062117-120931. Epub 2018 Jan 18. Annu Rev Biomed Eng. 2018. PMID: 29345977 Free PMC article. Review.
-
Astatine-211 radiolabelling chemistry: from basics to advanced biological applications.EJNMMI Radiopharm Chem. 2024 Oct 4;9(1):69. doi: 10.1186/s41181-024-00298-4. EJNMMI Radiopharm Chem. 2024. PMID: 39365487 Free PMC article. Review.
-
Astatine-211 based radionuclide therapy: Current clinical trial landscape.Front Med (Lausanne). 2023 Jan 6;9:1076210. doi: 10.3389/fmed.2022.1076210. eCollection 2022. Front Med (Lausanne). 2023. PMID: 36687417 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources